It’s an interesting take, but according to David Staples of the Edmonton Journal, the Edmonton Oilers are about to feel some blowback from the Mattias Ekholm trade. Arguing that the piece the Oilers ...

Natural cleaners like vinegar are not only effective, but they’re also healthier and gentler than many commercial cleaners. They can be used in numerous ways around the house rather than requiring ...

In addition to cosmetic imperfections like odors and discoloration, tap water can contain trace amounts of microplastics, VOCs and PFAS. The best countertop water filters help reduce the presence of ...

After testing the Kindle Scribe Colorsoft for two months, I found that it was made for a very specific kind of notetaker and reader. While the device is pretty and lightweight, it’s not something the ...

Posts from this topic will be added to your daily email digest and your homepage feed. The included stylus is great for writing or annotating notes when you aren’t reading ebooks. The included stylus ...

Shares of Scribe Therapeutics, a genetic-medicines company co-founded by Nobel laureate Jennifer Doudna, shot up on their first day of trading Friday, continuing a rebound for biotech IPOs this year.

This article first appeared on GuruFocus. Scribe Therapeutics (NASDAQ:SCTX), a clinical-stage developer of gene therapies for heart disease, surged 67% on Friday after raising $128.7 million in an ...

Scribe Therapeutics (SCTX), a gene therapy developer whose collaborators include Sanofi (SNY) and Eli Lilly (LLY), rose nearly 50% in its first trading session as a public company on Friday after an ...

Scribe Therapeutics (Nasdaq: SCTX) visits the Nasdaq MarketSite in Times Square. Scribe is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to ...

Scribe Therapeutics has overshot its own expectations with an IPO that's set to bring in $128.7 million for the in vivo gene editing outfit. Scribe is issuing 8.6 million shares—above the 7.1 million ...

For many people, managing a disease means chronic therapy. Scribe Therapeutics has a different vision: genetic medicines that offer durable effects for the masses. With its lead program on a path to ...